Oncology Data Advisor - Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma
ASCO 2023: Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-up of Lenvatinib + Pembrolizumab vs Sunitinib in Patients with Advanced RCC
Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma | Anticancer Research
Non-Small Cell Lung Cancer
Outcomes of Patients With Advanced Renal Cell Carcinoma With Non-Clear Cell Histology Treated With Systemic Therapy - Clinical Genitourinary Cancer
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing | World Journal of Surgical Oncology | Full Text
MP47-11 DIFFERENTIAL ASSOCIATION OF BODY MASS INDEX ON SURVIVAL OUTCOMES IN RENAL CELL CARCINOMA: IMPACT OF TUMOR HISTOLOGY | Journal of Urology
Decreased expression of JMJD3 predicts poor prognosis of patients with clear cell renal cell carcinoma
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Kaplan–Meier curves depicting overall survival (OS; a, b) and... | Download Scientific Diagram
ASCO 2022: Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations
ASCO 2023: Final Prespecified Overall Survival Analysis of CLEAR: 4-Year Follow-up of Lenvatinib + Pembrolizumab vs Sunitinib in Patients with Advanced RCC
Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma - Figure f3 | Aging
Prognostic Value of Serum CA9 in Patients with Metastatic Clear Cell Renal Cell Carcinoma under Targeted Therapy | Anticancer Research
Artificial intelligence prediction model for overall survival of clear cell renal cell carcinoma based on a 21-gene molecular prognostic score system - Figure f1 | Aging
Six RNA binding proteins (RBPs) related prognostic model predicts overall survival for clear cell renal cell carcinoma and is associated with immune infiltration | Biomolecules and Biomedicine
Oncotarget: Identification intermediate-risk | EurekAlert!
Kaplan–Meier estimates the (A) cancer-specific and (B) overall survival... | Download Scientific Diagram
BioCentury - The latest twist in the overall survival debate
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
Overall survival vs immunohistochemistry. The Kaplan Meier graph... | Download Scientific Diagram
Kaplan–Meier curves depicting overall survival (OS; a, b) and... | Download Scientific Diagram
CLEAR Study: First-Line Lenvatinib Plus Pembrolizumab Maintains Advantage Over Sunitinib in Advanced RCC at Long-Term Follow-up
